Skip navigation

U.S. FDA puts hold on Vertex hepatitis study; shares fall

(Reuters) - Vertex Pharmaceuticals Inc said U.S. health regulators placed a partial clinical hold on its mid-stage study of an experimental oral hepatitis C treatment because of potential liver problems, sending its shares sharply lower on Thursday. Full story

Screen middle-aged adults for hepatitis C: panel

NEW YORK (Reuters Health) - Adults born between 1945 and 1965 should be screened once for hepatitis C, a government-backed panel recommended today. Full story

Many in U.S. don't get proper testing for hepatitis C: CDC

NEW YORK (Reuters) - Only half of people in the United States who have ever been infected with hepatitis C get proper testing for the liver-destroying disease, U.S. health officials said on Tuesday. Full story

Bristol-Myers oral hepatitis C regimen looks competitive: study

(Reuters) - A combination of three experimental Bristol-Myers Squibb hepatitis C drugs appeared to be highly effective, according to data from a mid-stage clinical trial, keeping the company in the race for developing an all-oral treatment regimen for the serious liver disease. Full story

Dozens of Oklahoma dentist's patients test positive for hepatitis

OKLAHOMA CITY (Reuters) - Blood tests conducted on patients treated at an Oklahoma oral surgery practice that has been closed over health concerns show that 57 have hepatitis C, three have hepatitis B and as many as three have HIV, the virus than can lead to AIDS, officials said on Thursday. Full story

UnitedHealth units hit with $500 million verdict in hepatitis case

(Reuters) - A Nevada jury awarded $500 million in punitive damages in a closely watched case against two affiliates of UnitedHealth Group stemming from a hepatitis C outbreak in the state, according to a spokeswoman for a law firm in the case. Full story

Sponsored Links

Articles

Lawyer defends record of Oklahoma dentist in HIV-exposure scare

Statins tied to lowered liver cancer risk with hepatitis C

EU expands use of Roche's Pegasys in chronic hepatitis C

Even moderate drinking may be risky with hepatitis C

Gilead hepatitis C drug meets goal of fourth late-stage study

Gilead's two hepatitis C drug trials meet study goals

Suspect in hepatitis C outbreak wrote suicide note

Hepatitis C deaths up, boomers most at risk

New liver for alcoholics? Study reopens debate

Couple sues after he gets her infected kidney

Video

  Victim of dental office HIV scare: ‘I just want to get the testing over with’

Hundreds of people anxiously awaiting their medical fate after lining up for hepatitis and HIV tests have one thing in common -- they were patients of Dr. Scott Harrington, whose dental practice is now at the center of a health scare. NBC’s Charles Hadlock reports.

  Dentist’s patients line up for HIV, hepatitis tests

Patients of a Tulsa oral surgeon accused of unsanitary practices waited in line to discover whether they had been exposed to hepatitis or HIV. NBC’s Charles Hadlock reports.

  Thousands of dental patients at risk for HIV, Hepatitis

The Board of Dentistry accuses Dr. Scott Harrington of being a “menace to public health” after his patients were exposed to rusty equipment and re-used needles and drug vials. NBC’s Gabe Gutierrez reports.

  CDC: Boomers must get tested for hepatitis C

It’s estimated that one in 30 baby boomers – those born between 1945 and 1965 -- are infected with hepatitis C. Now the government is asking that everyone who falls within that age group to get tested. NBC’s Dr. Nancy Snyderman reports.

  Hepatitis C Drugs Show Promise

A new study testing experimental drugs from Gilead Sciences and Bristol-Myers showed some promising data for patients with the hepatitis C virus, reports CNBC's Seema Mody.

advertisement | ad info

Related Photos

An employee checks a hepatitis B vaccine, at SciVac's laboratory in Rehovot
An employee checks a hepatitis B vaccine, at SciVac's laboratory in Rehovot

An employee checks a Sci-B-Vac, a hepatitis B vaccine, at SciVac's laboratory in the central Israeli city of Rehovot July 14, 2013. REUTERS/Baz Ratner

Researchers monitor the manufacturing process of a hepatitis B vaccine at SciVac's laboratory in Rehovot
Researchers monitor the manufacturing process of a hepatitis B vaccine at SciVac's laboratory in Rehovot

Researchers monitor the manufacturing process of Sci-B-Vac, a hepatitis B vaccine, at SciVac's laboratory in the central Israeli city of Rehovot July 14, 2013. The Israeli drug company SciVac is seeking U.S. approval for the widely used hepatitis B vaccine as part of a push for increased global sale